Russian pharma manufacturers shipped the medicines worth 271 billion rubles

Print 28 November 2017
GMP News

In January-October 2017, Russian pharmaceutical manufacturers shipped from their warehouses the medicinal products worth 271 billion rubles (ex warehouse prices, including VAT).

In ruble-denominated terms, this amounted to the 5.8% growth compared to the same period of the previous year. The growth in physical terms is less and stands at only 1.6%. Overall, in the first 10 months of this year, the pharmaceutical companies supplied to the market 3.45 billion packages of medicinal products.

The results of operations in October 2017 were not a breakthrough neither in monetary, nor in physical terms. The shipments reached 29.7 billion rubles or 0.37 billion packages. Compared to October 2016, this was a decline of 4% in ruble-denominated monetary terms or decline of 2.1% in terms of physical packages. At the same time, the overall dynamics are within the seasonal trends – the short-term period (compared to September 2017) demonstrated the growth in both monetary and physical volumes. However, so far, it is difficult to predict whether this trend will continue in the long run, as there are differences from the patterns of previous years.

In addition, in the 10 months since the start of this year, the gains in the shipments of Russian companies both in monetary and physical volumes still lag behind of those registered for imported products. In January-October 2017, the imports of finished medicinal products to Russia reached 420 billion rubles (in prices including the customs clearance). In ruble-denominated terms, this is an increase of 8.9% compared to the same period of the previous year. In physical terms (packages), the imports grew by 5.9%; overall, in 10 months, the importers brought to Russia 1.65 billion packages of finished medicinal products.

Source

Return